Skip to main content
Advertisement
Advertisement
ACET
ACET logo
Adicet Bio, Inc. Common Stock
3.00
USD
Sponsored
+0.01
+0.33%
Nov 10, 15:58 UTC -5
Closed
exchange

After-Market

2.99

-0.01
-0.33%

Adicet Bio, Inc. Common Stock (ACET) Earnings

ACET Earnings Reports

Positive Surprise Ratio

ACET beat 18 of 36 last estimates.

50%

Next Report

Date of Next Report
Mar 10, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/
-$1.70
Implied change from Q3 26 (Revenue/ EPS)
--
/
-3.41%
Implied change from Q4 25 (Revenue/ EPS)
--
/
-42.18%

Adicet Bio, Inc. Common Stock earnings per share and revenue

On Nov 05, 2026, ACET reported earnings of -1.76 USD per share (EPS) for Q3 26, missing the estimate of -1.62 USD, resulting in a -8.64% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +4.45% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -1.70 USD, with revenue projected to reach -- USD, implying an decrease of -3.41% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
logo
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
logo
CalciMedica, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$1.30
Actual
-$0.72
Surprise
+44.64%
logo
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
logo
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
logo
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
logo
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
logo
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
logo
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
logo
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
FAQ
For Q3 2026, Adicet Bio, Inc. Common Stock reported EPS of -$1.76, missing estimates by -8.64%, and revenue of $0.00, 0% as expectations.
The stock price moved up 4.45%, changed from $2.92 before the earnings release to $3.05 the day after.
The next earning report is scheduled for Mar 10, 2027.
Based on -- analysts, Adicet Bio, Inc. Common Stock is expected to report EPS of -$1.70 and revenue of -- for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement